Clinical Trial Update: A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of tandutinib in newly diagnosed acute myeloid leukemia patients who are ineligible for or decline standard induction therapy has been withdra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tandutinib (tandutinib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN